特立帕肽治疗导致迟发性显著高钙血症:一例病例报告及文献综述
报告一例72岁女性骨质疏松患者在接受特立帕肽治疗约3个月后出现迟发性显著高钙血症(血钙3.30 mmol/l),停药并补液后血钙恢复,再次用药后高钙血症复发,最终换用地舒单抗。文献复习提示特立帕肽所致迟发性中重度高钙血症(血钙>3.0 mmol/l)罕见但可能导致治疗中止,易感因素尚不明确,强调治疗期间常规监测血钙的重要性。
要点
- 特立帕肽所致迟发性高钙血症(注射后>24小时)罕见,但本病例出现显著高钙血症(血钙3.30 mmol/l)。
- 停药并补液后血钙恢复正常,再次使用特立帕肽后高钙血症复发,提示药物相关。
- 特立帕肽治疗期间应常规监测血清钙,以及时发现迟发性高钙血症。
核心结论
- 特立帕肽所致迟发性中重度高钙血症(血清钙>3.0 mmol/l)罕见但可能导致治疗中止。
- 易感风险因素尚不明确,强调治疗期间常规评估血清钙的重要性。
研究设计与样本
- 病例报告:一例72岁女性骨质疏松患者接受特立帕肽治疗后出现迟发性高钙血症,并结合文献复习其他病例。
主要发现
- 患者治疗前血清钙正常为2.39 mmol/l,治疗约3个月后 routine 检测发现高钙血症,血钙3.30 mmol/l。
- 检查显示血清25-羟基维生素D为94 nmol/l,甲状旁腺激素降低为6.0 pg/ml,1,25二羟维生素D正常为115 pmol/l,甲状旁腺激素相关肽<1.4 pmol/ml,血清电泳和血管紧张素转换酶(39 IU/l)正常。
- 腹部、盆腔和胸部CT未见恶性肿瘤证据,同位素骨扫描排除骨骼转移。
- 停用特立帕肽和钙补充剂并给予静脉补液后数日,血清钙恢复正常为2.34 mmol/l。
- 再次使用特立帕肽后迟发性高钙血症复发,治疗换用地舒单抗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Transient hypercalcaemia due to teriparatide occurs in up to 11% of patients though delayed hypercalcaemia (> 24 h post injection) is rare. We report the case of a female who developed significant delayed hypercalcaemia after teriparatide treatment for osteoporosis and review other cases in the literature to date. CASE REPORT: A 72-year-old female on teriparatide for the treatment of osteoporosis was found to have hypercalcaemia (3.30 mmol/l) on routine testing approximately 3 months after starting therapy. Serum calcium pretreatment was normal at 2.39 mmol/l. She was admitted to the hospital for investigations which identified a serum 25-hydroxyvitamin D of 94 nmol/l, a low parathyroid hormone of 6.0 pg/ml, and normal test results for 1,25 dihydroxyvitamin D (115 pmol/l), parathyroid hormone-related peptide (< 1.4 pmol/ml), serum electrophoresis and angiotensin-converting enzyme (39 IU/l). CT abdomen, pelvis, and thorax revealed no evidence of malignancy and an isotope bone scan ruled out skeletal metastases. Serum calcium normalised (2.34 mmol/l) several days after stopping teriparatide and calcium supplements and administering intravenous fluid. On restarting teriparatide, delayed hypercalcaemia reoccurred and treatment was switched to denosumab. DISCUSSION: Delayed moderate to severe hypercalcaemia (serum calcium > 3.0 mmol/l) due to teriparatide is rare but may lead to therapy withdrawal. The underlying predisposing risk factors remain unclear and highlight the importance of a routine serum calcium assessment on therapy.
引用
- McCarroll K, Carroll T, Neville M, et al. Delayed and significant hypercalcaemia due to teriparatide therapy: a case report and review. Osteoporos Int. 2024. PMID: 38613637. doi:10.1007/s00198-024-07082-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。